SCHEDULE: Tasso Partners, Dana Carrera Disclose 9.99% DarioHealth Stake

Tasso Partners, LLC and Dana Carrera have filed an amended Schedule 13G, reporting a combined beneficial ownership of 9.99% in DarioHealth Corp. common stock and pre-funded warrants.

Summary

• Tasso Partners, LLC and Dana Carrera (collectively, "Reporting Persons") have filed an amended Schedule 13G, indicating their beneficial ownership in DarioHealth Corp.
• Both Reporting Persons beneficially own 676,141 shares of DarioHealth Corp. common stock, representing 9.99% of the class.
• This ownership includes 612,558 shares of common stock held by Tasso Partners, LLC.
• It also includes pre-funded warrants exercisable into 1,113,078 shares of common stock, which are subject to a contractually stipulated 9.99% ownership restriction. These warrants are beneficially owned by Dana Carrera as the trustee of GCL Family Trust.
• Dana Carrera also holds sole voting and dispositive power over 6,250 shares of common stock owned by the GCL Family Trust.
• The percentage ownership is calculated based on 6,768,184 common shares outstanding as of the filing date.
• All share numbers reflect a 1-for-20 reverse stock split effected by DarioHealth Corp. on August 28, 2025.
• The filing states that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently sway sentiment positively or negatively regarding the issuer's performance or prospects. The 9.99% stake is significant but not new, as it's an amendment.

Positives

• A significant institutional investor and individual (Tasso Partners, LLC and Dana Carrera) maintain a substantial stake (9.99%) in DarioHealth Corp., potentially signaling confidence in the company's long-term prospects.
• The contractual 9.99% ownership restriction on pre-funded warrants indicates a strategic approach to maintaining a significant but non-controlling interest.

Risks

• The existence of pre-funded warrants, while common, could lead to future dilution if exercised, although the 9.99% ownership restriction limits immediate impact.
• A significant portion of the reported ownership is through shared voting and dispositive power, indicating a coordinated investment strategy between Tasso Partners, LLC and Dana Carrera.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by Tasso Partners, LLC and Dana Carrera provides transparency regarding the company's ownership structure. The 9.99% restriction on warrants limits immediate dilution from those specific instruments.
• Management: Awareness of a significant investor group holding a near-10% stake may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

This Schedule 13G filing primarily provides transparency on a significant beneficial ownership stake by Tasso Partners, LLC and Dana Carrera in DarioHealth Corp. It does not contain financial performance data, strategic updates, or other information typically used to form a 'buy' or 'sell' recommendation. The maintenance of a near-10% stake, including pre-funded warrants with a contractual ownership restriction, suggests a continued, stable investment position. Without further operational or financial details from the company, a 'hold' recommendation is appropriate, indicating no new information to change an existing investment thesis based solely on this ownership disclosure.

Keywords

DarioHealth Corp., Schedule 13G, beneficial ownership, common stock, pre-funded warrants, Tasso Partners LLC, Dana Carrera, reverse stock split, institutional investment, equity stake